Amgen released positive data for two immunotherapies in its BiTE platform, treating acute myeloid leukemia and multiple myeloma, the latter of which has been fast-tracked for development by the U.S. Food and Drug Administration. The Thousand Oaks-based biotech giant announced Dec. 3 that its AMG 420 and AMG 330 immunotherapies had both shown early evidence…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
